SANTA CLARA, Calif.—February 20, 2018—Cardiva Medical®, an innovator in the field of vascular closure, today announced that the company has closed on $11 million in additional financing — bringing total equity and debt financing in the current round to $41 million.

Longview Regional Medical Center in Texas co-hosted a “Play it Safe” event inviting teenagers across East Texas and surrounding areas to participate in free heart checkups. Now in its fifth year, the event was also hosted by Championship Hearts Foundation, a nonprofit that focuses on preventing sudden cardiac death among youth.

COPENHAGEN, February 8, 2018 — Acesion Pharma ("Acesion" or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018.

For nearly 6,000 patients with heart failure and chronic kidney disease (CKD), the use of an implantable cardioverter defibrillator (ICD) showed no mortality benefit but a higher risk of subsequent hospitalizations after covariate adjustment, researchers reported in JAMA Internal Medicine.

Catheter ablation was associated with significantly fewer deaths and hospitalizations for worsening heart failure than medical therapy in a randomized trial of patients with atrial fibrillation (AFib) and heart failure.

A pair of researchers at Utah State University are aiming to revolutionize the world of digital monitoring with a new technology that can measure a person’s heartbeat using nothing more than a video camera and specialized software, the university announced Monday.

Four in ten cardiomyopathies are familial, suggesting an urgent need for more widespread genetic testing, a team of cardiologists reported in the European Heart Journal this week.

In his 17 years as a dentist, Robert Camenzuli has seen allergic reactions, chest pains and seizures cycle through his office. But this January came with a first—a 53-year-old patient who went into cardiac arrest.